Keywords: Algeta, Bayer, Alpharadin, licensing

Algeta signs $800 million deal with Bayer for Alpharadin in bone metastases

Article | 03 September 2009

Print This

Algeta ASA, a Norwegian cancer therapeutics company, has entered into a global agreement with German drug major Bayer for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in